The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question
MS Treatments
Jahr
Publikationsjahr
2017
Autoren
Autorenliste der Publikation
D'Amico E, Ziemssen T, Cottone S.
Verlag
Publisher-Information
Expert Rev Neurother 2017;17(9):847-849.
Link
Zur Publikation (externer Server)
https://doi.org/10.1080/14737175.2017.1340831
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2017
Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.
MS Treatments
Jahr
2025
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
MASC
Jahr
2025
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
NIL
Jahr
2025
